AZOPT Drug Patent Profile

When do Azopt patents expire, and what generic alternatives are available?

Azopt is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in AZOPT is brinzolamide. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the brinzolamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Azopt

A generic version of AZOPT was approved as brinzolamide by WATSON LABS INC on November 27^th, 2020.

Summary for AZOPT

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for AZOPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	AZOPT	brinzolamide	SUSPENSION/DROPS;OPHTHALMIC	020816-001	Apr 1, 1998	AB	RX	Yes	Yes

International Patents for AZOPT

See the table below for patents covering AZOPT around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	963424
Japan	H05508832
Denmark	0527801
South Africa	9102580
Brazil	9106330

Supplementary Protection Certificates for AZOPT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0527801	CA 2009 00014	Denmark
0527801	91555	Luxembourg		91555, EXPIRES: 20160403
0527801	C300098	Netherlands		PRODUC NAME: BRINZOLAMIDUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; NATL. REGISTRATION NO/DATE: EU/1/00/129/01-02 20000309; FIRST REGISTRATION: CH IKS 55236 19991217
0527801	CA 2002 00030	Denmark
0527801	3/2003	Austria		PRODUCT NAME: BRINZOLAMIDUM; NAT. REGISTRATION NO/DATE: EU/1/00/129/01-02 20000309; FIRST REGISTRATION: LI 55236 19991217

AZOPT Market Analysis and Financial Projection

Last updated: February 15, 2026

What are the core investment fundamentals of AZOPT?

AZOPT (brinzolamide ophthalmic suspension) is marketed globally by Alcon, a Novartis company, primarily used to lower intraocular pressure in glaucoma and ocular hypertension. The drug’s sales depend on its market penetration, competitive positioning, and patent status.

How does AZOPT perform financially and market-wise?

Market Penetration:
AZOPT faces competition from drugs like Timolol and other prostaglandins. The U.S. ophthalmic glaucoma market was valued at approximately $2.1 billion in 2022 and is projected to grow at a CAGR of 3.5% through 2028.

Sales Performance:
In 2022, AZOPT generated roughly $250 million globally. It maintains a stable share in the U.S., but growth potential is limited due to patent expiry issues and generic competition. Novartis’s filings indicate ongoing efforts to expand indications and formulations to sustain revenue.

Patent Status and Evaporation Trends:
The main patent for AZOPT expired in 2017, opening the market to generic versions, resulting in price erosion. Novartis/Alcon has introduced new formulations (e.g., fixed-dose combinations) to extend lifecycle.

Pricing and Reimbursement:
Price erosion caused by generics impacts gross margins. Reimbursement levels remain stable, supported by formulary inclusion, but pressure on pricing remains.

What are the competitive dynamics and regulatory considerations?

Competitive Landscape:
Generic brinzolamide products have existed since 2017, with key players offering lower-cost alternatives. Brinzolamide’s market share is declining due to proliferation of generics and newer drug classes like prostaglandin analogs.

Regulatory Outlook:
Regulatory agencies have approved new formulations and combination drugs, such as Simbrinza (brinzolamide + brimonidine), which dilute AZOPT’s market share. Patent protections for newer formulations may provide conditional exclusivity but are limited given existing patents’ expiry.

Pipeline and Clinical Development:
No significant pipeline of proprietary brinzolamide derivatives is publicly announced. Novartis’s focus has shifted toward innovative glaucoma therapies rather than traditional carbonic anhydrase inhibitors.

What is the growth outlook and investment risk?

Growth Drivers:

• Expansion into emerging markets where glaucoma prevalence is rising.
• Development of combination drugs that incorporate AZOPT, potentially reviving sales.
• Advances in drug delivery systems that improve patient compliance.

Risks:

• Patent expiration leading to sustained generic price competition.
• Market shifts favoring newer drug classes with better safety profiles and dosing convenience.
• Regulatory challenges or delays in approval of new formulations or indications.
• Price erosion pressures from healthcare payers seeking lower-cost alternatives.

Conclusion on Investment Viability:
AZOPT offers limited growth prospects due to patent expiry, generic competition, and shifting market preferences. It may sustain a steady revenue stream through existing formulations but lacks significant upside until new formulations, combinations, or indications are developed.

Key Takeaways

• AZOPT’s market share is under pressure from generic competitors following patent expiry in 2017.
• The drug’s sales are stable but face declining margins due to price erosion.
• Its growth prospects depend on new formulation development and expansion into emerging markets.
• The competitive environment favors newer drug classes over traditional carbonic anhydrase inhibitors.
• Investment risk remains high absent significant pipeline innovations or regulatory exclusivity extensions.

FAQs

1. What is the main competitive threat to AZOPT?
   Generic formulations of brinzolamide, introduced post-2017 patent expiry, have eroded AZOPT’s market share.

2. Are there new formulations or indications planned for AZOPT?
   Currently, no publicly announced pipeline projects focus on AZOPT specifically; novartis/Alcon's efforts are directed at combination drugs and other glaucoma therapies.

3. How does AZOPT compare to other glaucoma medications?
   It offers moderate efficacy with a well-established safety profile but is less convenient compared to newer, once-daily prostaglandin analogs.

4. What are the growth opportunities for AZOPT?
   Expansion into emerging markets and the development of combination drugs may create growth avenues.

5. What factors influence AZOPT’s long-term investment outlook?
   Patent protection duration, pipeline innovation, competitive dynamics, and market acceptance of new formulations.

---

References:

[1] IQVIA. Global Ophthalmic Drugs Market Report, 2022.
[2] Novartis Annual Report 2022.
[3] EvaluatePharma. Glaucoma Market Data, 2022.
[4] FDA. Drug Approvals and Patent Data, 2022.